Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy
NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy.
-
NICE announces more people eligible for nusinersen following review of Managed Access Agreement
NICE has today (4 May 2021) announced that more people with the rare genetic disorder spinal muscular atrophy (SMA) are to benefit from nusinersen (also called Spinraza and made by Biogen) following a review of data collected as part of the Managed Access Agreement (MAA).
-
New draft guidance aims to achieve fairer outcomes for looked-after children and young people
Looked after children and young people should be considered ‘one of their own’ by carers, in order to help them to reach their full potential, new NICE draft guidelines say.
-
NICE signs up to join the GetReal Institute
NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence in health care decision-making.
